Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2013

View Archived Issues

Companies enter collaboration to develop Tregitope immune-modulating technology

Boston Scientific set to launch Promus Premier stent system in Europe

Japanese authorities remove condition for approval from Abraxane

Priority review granted to Bayer's NDA for radium-223

Amylin Pharmaceuticals patents new fusion proteins

GlaxoSmithKline presents novel TRPV4 antagonists

GlaxoSmithKline discloses novel tyrosine-protein kinase inhibitors

AstraZeneca synthesizes new inhibitors of mutated forms of EGFR

Pfizer designs new glucagon receptor antagonists

Xenetic Biosciences signs research agreement

ALX-0061 demonstrates good efficacy and safety in RA patients

Agilent Technologies and Sera Prognostics form partnership

Dako and Pfizer to collaborate on companion diagnostics

Peregrine Pharmaceuticals reports results from phase II bavituximab trial

Xencor begins phase Ib/IIa trial of XmAb-5871

GGF2 enhances post-stroke recovery of sensorimotor functions in vivo

Prolor Biotech's hGH-CTP receives orphan drug designation in Europe

Phase III Fibrocaps trial achieves safety milestone

Phase III study finds no benefit for DP-b99 in acute ischemic stroke

Lundbeck reflects on highlights of 2012

Novo Nordisk gains price approval in Japan for once-daily basal insulin

EMA grants orphan designation to BHR Pharma's investigational agent for traumatic brain injury

Photoimmunotherapy enhances accumulation of nanosized chemotherapy in tumors

Lentigen obtains FDA orphan designation for novel gene therapy for glioblastoma multiforme

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...